Vijay K. Ramanan
A5028946052- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Genetic Associations and Epidemiology
- Parkinson's Disease Mechanisms and Treatments
- Advanced Neuroimaging Techniques and Applications
- Health, Environment, Cognitive Aging
- Genomics and Rare Diseases
- Bioinformatics and Genomic Networks
- Functional Brain Connectivity Studies
- Genetics and Neurodevelopmental Disorders
- Neurological Disease Mechanisms and Treatments
- Amyotrophic Lateral Sclerosis Research
- Genomic variations and chromosomal abnormalities
- Neurological diseases and metabolism
- Folate and B Vitamins Research
- Health Systems, Economic Evaluations, Quality of Life
- Epigenetics and DNA Methylation
- Diet and metabolism studies
- Prion Diseases and Protein Misfolding
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Mitochondrial Function and Pathology
- Intracerebral and Subarachnoid Hemorrhage Research
- Bone and Joint Diseases
- Nuclear Receptors and Signaling
- Frailty in Older Adults
Mayo Clinic
2018-2025
Mayo Clinic in Arizona
2018-2025
WinnMed
2020-2025
Imaging Center
2024
University College London
2024
Cornell University
2024
Mayo Clinic in Florida
2021-2024
VIB-UAntwerp Center for Molecular Neurology
2024
University of Antwerp
2024
University of California, Los Angeles
2024
Treatment options for Alzheimer disease (AD) are limited and have focused mainly on symptomatic therapy improving quality of life. Recently, lecanemab, an anti-β-amyloid monoclonal antibody (mAb), received accelerated approval by the US Food Drug Administration treatment in early stages biomarker-confirmed AD. An additional mAb, aducanumab, was approved 2021, more will potentially become available near future. Research applicability generalizability mAb eligibility criteria adults with...
Abstract Staging the severity of Alzheimer’s disease pathology using biomarkers is useful for therapeutic trials and clinical prognosis. Disease staging with amyloid tau PET has face validity; however, this would be more practical plasma biomarkers. Our objectives were, first, to examine approaches and, second, prediction stages Participants (n = 1136) were enrolled in either Mayo Clinic Study Aging or Research Center; had a concurrent PET, blood draw; met criteria cognitively unimpaired...
Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging eligibility assessment as well monitoring amyloid-related abnormalities. Amyloid-related abnormalities result from treatment-related loss of vascular integrity and may occur in 2 forms. with edema or effusion transient, treatment-induced sulcal effusion, identified on T2-FLAIR. hemorrhage microhemorrhages superficial siderosis T2* gradient recalled-echo. As monoclonal become...
Abstract BACKGROUND We compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates memory decline among cognitively unimpaired individuals. METHODS studied 645 Mayo Clinic Study Aging participants. Predictor variables were age, sex, education, apolipoprotein E ( APOE ) ε 4 genotype, PET, and beta (Aβ)42/40, phosphorylated tau (p‐tau)181, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), p‐tau217. The outcome was a...
Brain amyloid deposition is thought to be a seminal event in Alzheimer's disease. To identify genes influencing disease pathogenesis, we performed genome-wide association study of longitudinal change brain burden measured by (18)F-florbetapir PET. A novel with higher rates accumulation independent from APOE (apolipoprotein E) ε4 status was identified IL1RAP (interleukin-1 receptor accessory protein; rs12053868-G; P = 1.38 × 10(-9)) and validated deep sequencing. rs12053868-G carriers were...
Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of susceptibility, diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows promise as biomarker, but studies have largely focused only on core FTD syndromes, often grouping patients with different diagnoses. To expedite the clinical translation NfL, we avail ARTFL LEFFTDS Longitudinal Lobar Degeneration (ALLFTD) study resources conduct comprehensive investigation plasma NfL across syndromes in...
Recent advances in blood-based biomarkers offer the potential to revolutionize diagnosis and management of Alzheimer disease (AD), but additional research diverse populations is critical. We assessed profiles AD their relationships cognition common medical comorbidities a biracial cohort.
Abstract Amyloid PET imaging has been crucial for detecting the accumulation of amyloid beta (Aβ) deposits in brain and to study Alzheimer’s disease (AD). We performed a genome-wide association on largest collection data (N = 13,409) date, across multiple ethnicities from multicenter cohorts identify variants associated with amyloidosis AD risk. found strong APOE signal chr19q.13.32 (top SNP: ɛ4; rs429358; β 0.35, SE 0.01, P 6.2 × 10 –311 , MAF 0.19), driven by ɛ4, five additional novel...
Abstract INTRODUCTION We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p‐tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status implementation in practice. METHODS Clinical performance p‐tau217 against positron emission tomography was evaluated participants with mild cognitive impairment or dementia ( n = 427). RESULTS Using a one‐cutpoint approach (negative/positive), neither assay achieved ≥ 90% both sensitivity specificity. A...
Abstract INTRODUCTION Patients with dementia Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate biomarkers of AD and their association positron emission tomography (PET) amyloid tau deposition in the continuum DLB, starting from prodromal stages disease. METHODS The cohort included patients isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment (MCI‐LB), or a concurrent...
Importance Frontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers trial recruitment success, but no such tools validated for FTLD. Objective To evaluate the reliability validity of measures remote FTLD evaluations. Design, Setting, Participants In this cohort study conducted from...
Abstract Predominant limbic degeneration has been associated with various underlying aetiologies and an older age, predominant impairment of episodic memory slow clinical progression. However, the neurological syndrome is not defined. This endeavour critical to distinguish such a from those originating neocortical degeneration, which may differ in aetiology, disease course therapeutic needs. We propose set criteria for limbic-predominant amnestic neurodegenerative that highly age-related...
Abstract In the Alzheimer’s disease (AD) continuum, prodromal state of mild cognitive impairment (MCI) precedes AD dementia and identifying MCI individuals at risk progression is important for clinical management. Our goal was to develop generalizable multivariate models that integrate high-dimensional data (multimodal neuroimaging cerebrospinal fluid biomarkers, genetic factors, measures resilience) identification who progress within 3 years. main findings were i) we able build with...